Research output per year
Research output per year
Personal profile
Expertises
- Design of clinical trials according to Good Clinical Practice
- Work in lab: Cell culturing, flowcytometry
- Especially knowledge in malignant melanoma
Main research areas
Oncology: In more detail cancer immunotherapy: The use of a persons immune system to fight cancer; i.e. with monoclonal antibodies, cancer vaccines and T cell therapy. My main research area is to test safety, toxicity an clinical efficacy of peptide vaccines consisting of PD-L1 and IDO peptides in combination with the standard treatment Nivolumab (PD-1 blocking antibody) (first in patient with malignant melanoma, and hopefully expand to other cancer types).
Current research
Clinical trial with the title: "Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. Inclusion of the first patient in March 2017.
Potential conflicts of interest
No conflicts of interest
Fingerprint
Dive into the research topics where Julie Westerlin Kjeldsen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer
Mørk, S. K., Kongsted, P., Westergaard, M. C. W., Albieri, B., Granhøj, J. S., Donia, M., Martinenaite, E., Holmström, M. O., Madsen, K., Kverneland, A. H., Kjeldsen, J. W., Holmstroem, R. B., Lorentzen, C. L., Nørgaard, N., Andreasen, L. V., Wood, G. K., Christensen, D., Klausen, M. S., Hadrup, S. R., Thor Straten, P., & 2 others, 14 Mar 2023, In: Frontiers in Immunology. 14, p. 1122977 15 p., 1122977.Research output: Contribution to journal › Journal article › Research › peer-review
-
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial
Lorentzen, C. L., Martinenaite, E., Kjeldsen, J. W., Holmstroem, R. B., Mørk, S. K., Pedersen, A. W., Ehrnrooth, E., Andersen, M. H. & Svane, I. M., 17 Oct 2022, In: Frontiers in Immunology. 13, p. 1023023 1023023.Research output: Contribution to journal › Journal article › Research › peer-review
-
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Kjeldsen, J. W., Lorentzen, C. L., Martinenaite, E., Ellebaek, E., Donia, M., Holmstroem, R. B., Klausen, T. W., Madsen, C. O., Ahmed, S. M., Weis-Banke, S. E., Holmström, M. O., Hendel, H. W., Ehrnrooth, E., Zocca, M-B., Pedersen, A. W., Andersen, M. H. & Svane, I. M., Apr 2022, 1 p.Research output: Other contribution › Research
1 Citation (Scopus) -
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
Kverneland, A. H., Chamberlain, C. A., Borch, T. H., Nielsen, M., Mørk, S. K., Kjeldsen, J. W., Lorentzen, C. L., Jørgensen, L. P., Riis, L. B., Yde, C. W., Met, Ö., Donia, M. & Marie Svane, I., 4 Oct 2021, In: Journal for ImmunoTherapy of Cancer. 9, 10, e003499.Research output: Contribution to journal › Journal article › Research › peer-review
15 Citations (Scopus) -
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma
Klausen, U., Grønne Dahlager Jørgensen, N., Grauslund, J. H., Munir Ahmad, S., Gang, A. O., Martinenaite, E., Weis-Banke, S. E., Breinholt, M. F., Novotny, G. W., Kjeldsen, J. W., Orebo Holmström, M., Pedersen, L. B., Poulsen, C. B., Hansen, P. B., Met, Ö., Svane, I. M., Niemann, C. U., Pedersen, L. M. & Andersen, M. H., 2021, In: OncoImmunology. 10, 1, 1975889.Research output: Contribution to journal › Journal article › Research › peer-review
2 Citations (Scopus)